NASDAQ:CYTKCytokinetics Stock Price, Forecast & News

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYTK shares have increased by 88.4% and is now trading at $22.66.
View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cytokinetics.

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Cytokinetics.

Cytokinetics will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Cytokinetics, Inc. (NASDAQ:CYTK) released its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.16. The biopharmaceutical company had revenue of $3.83 million for the quarter, compared to analysts' expectations of $4.92 million.
View Cytokinetics' earnings history.

9 brokerages have issued 12-month target prices for Cytokinetics' shares. Their forecasts range from $20.00 to $59.00. On average, they anticipate Cytokinetics' share price to reach $37.22 in the next twelve months. This suggests a possible upside of 64.3% from the stock's current price.
View analysts' price targets for Cytokinetics.

News coverage about CYTK stock has trended somewhat negative on Tuesday, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cytokinetics earned a news impact score of -1.7 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Cytokinetics.

Cytokinetics saw a drop in short interest in June. As of June 30th, there was short interest totaling 7,720,000 shares, a drop of 6.3% from the June 15th total of 8,240,000 shares. Based on an average daily volume of 867,200 shares, the short-interest ratio is currently 8.9 days. Approximately 14.2% of the company's stock are sold short.
View Cytokinetics' Current Options Chain.

Some companies that are related to Cytokinetics include United Therapeutics (UTHR), Reata Pharmaceuticals (RETA), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Schrodinger (SDGR), Legend Biotech (LEGN), Arrowhead Pharmaceuticals (ARWR), HYPERA S A/S (HYPMY), Myokardia (MYOK), Evotec (EVTCY), Global Blood Therapeutics (GBT), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR) and Biohaven Pharmaceutical (BHVN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Geron (GERN), TherapeuticsMD (TXMD), Gilead Sciences (GILD) and Immunomedics (IMMU).

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Cytokinetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include New York State Teachers Retirement System (0.20%), Comerica Bank (0.11%), Oregon Public Employees Retirement Fund (0.04%), ProShare Advisors LLC (0.03%), Granite Investment Advisors LLC (0.03%) and SG Americas Securities LLC (0.03%). Company insiders that own Cytokinetics stock include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, Value Fund L P Biotechnology and Wendall Wierenga.
View institutional ownership trends for Cytokinetics.

CYTK stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, UBS Group AG, Envestnet Asset Management Inc., Dupont Capital Management Corp, and First Citizens Bank & Trust Co.. Company insiders that have sold Cytokinetics company stock in the last year include Bvf Partners L P/Il, Fady Ibraham Malik, Mark A Schlossberg, Robert I Blum, Sandford D Smith, Santo J Costa, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics.

CYTK stock was bought by a variety of institutional investors in the last quarter, including New York State Teachers Retirement System, Sigma Planning Corp, ProShare Advisors LLC, Comerica Bank, Granite Investment Advisors LLC, Zurcher Kantonalbank Zurich Cantonalbank , and Oregon Public Employees Retirement Fund. Company insiders that have bought Cytokinetics stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Cytokinetics.

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYTK stock can currently be purchased for approximately $22.66.

Cytokinetics has a market capitalization of $1.35 billion and generates $26.87 million in revenue each year. The biopharmaceutical company earns $-121,690,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Cytokinetics employs 130 workers across the globe.

The official website for Cytokinetics is www.cytokinetics.com.

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-624-3000 or via email at [email protected]